Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Brexanolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 3/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 3/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 3/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 1.00 |
| ▸ | G6PD | P11413 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brexanolone SCHEMBL23743678 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL23716709 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL25079438 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL23699798 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL23743691 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL23743739 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL24450442 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL23743720 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL24285706 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 | |
| Brexanolone SCHEMBL25079445 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP2C9GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4740024-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | The University Court Of The University of Edinburgh (GB) | 2026-05-13 | — | — | EP | claimed |
| US-12492221-B2 | Process for preparing (3α,5α)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone) | INDUSTRIALE CHIMICA S.R.L. (IT) | 2025-12-09 | — | — | US | claimed |
| US-20250367658-A1 | Systems And Methods For Semi-Quantitative And Quantitative Detection Of Metabolities Of Progesterone | EASY HEALTHCARE CORP (US) | 2025-12-04 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250205146-A1 | GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION | SISSA - SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI (IT) | 2025-06-26 | — | — | US | claimed |
| US-20250199014-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4530290-A2 | INJECTABLE SUSPENSIONS | Asarina Pharma AB (SE) | 2025-04-02 | — | — | EP | claimed |
| WO-1995005164-A1 | PARTICLES WITH MODIFIED PHYSICOCHEMICAL PROPERTIES, THEIR PREPARATION AND USES | WESTESEN KIRSTEN (DE) | 1995-02-23 | — | — | WO | claimed |
| WO-1995001162-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 1995-01-12 | — | — | WO | claimed |
| US-5232917-A | Tranquillizers; antianxiolytic agents; sedatives; antidepressants; anticonvulsants; neurotransmitters | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-08-03 | — | — | US | claimed |
| WO-1993003732-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-03-04 | — | — | WO | claimed |
| EP-0454773-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | Bundgaard, Hans (DK) | 1991-11-06 | — | — | EP | claimed |
| US-5028600-A | Oil in Water Emulsion of Pregnanolone | KABIVITRUM AB (SE) | 1991-07-02 | — | — | US | claimed |
| EP-0233849-B1 | COMPOSITION OF PREGNANOLOLE COMPRISING A STABLE OIL-IN-WATER EMULSION | Kabi Pharmacia AB (SE) | 1991-06-19 | — | — | EP | claimed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | claimed |
| EP-0233849-A1 | Composition of pregnanolole comprising a stable oil-in-water emulsion | Kabi Pharmacia AB (SE) | 1987-08-26 | — | — | EP | claimed |
| US-4663311-A | Derivatives of muramyl-peptides and of steroids having macrophage-activating properties | TENU JEAN P (FR) | 1987-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492221-B2 | Process for preparing (3α,5α)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone) | CYP17A1, CYP21A2, CYP4A11 | GABRA1 844/4885GABRG2 645/4885GABRB3 879/4885 |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | GABRA1 2057/4885GABRG2 2228/4885GABRB3 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.